
News|Articles|January 2, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-08-2014
- Volume 10
- Issue 1
BMS Grants Support Mental Health Needs of US Military Veterans
Author(s)Melanie Sena
The Bristol-Myers Squibb Foundation is awarding 10 grants to fund programs for veterans and their families.
Advertisement
The
The Foundation’s 2013 Mental Health and Well-Being grant recipients are:
- New York Legal Assistance Group and Connecticut Veterans Legal Clinic will receive two-year grants to partner with the Department of Veterans Affairs (VA) to study how civil legal services impact mental health and quality of life outcomes for veterans treated in VA mental health and homeless programs.
- Points of Light, National Council for Behavioral Health, and Massachusetts General Hospital will each receive two-year grants to partner with Outside the Wire on its Theater of War performances to military and civilian audiences in 25 US cities. Outside the Wire is a social impact company that uses theater to address a number of pressing public health issues.
- Minnesota Veterans Medical Research and Education Foundation will receive a two-year grant for a new program called Building Spiritual Strength that will use pastoral counselors to address the issues of moral injury – killing or wounding others – among combat trauma survivors.
- Rush University Medical Center Department of Behavioral Sciences will receive a one-year grant to complete an efficacy trial of the mental health services provided by Vets Prevail and recruit and enroll more than 6,200 additional veterans into the program, which received funding from the Foundation last year.
- Boston University School of Public Health will receive a two-year grant to transform a pilot version of a self-directed, web-based intervention that focuses on self-management to control alcohol consumption as a critical approach to managing PTSD into a consumer-ready version.
- National Alliance on Mental Illness (NAMI) received a three-year matching grant to adapt the evidence-based NAMI Family-to-Family Education Program to the needs of families of active duty military personnel and veterans.
- Carter Center received a grant to conduct the Mental Health & Well-Being Grantees Summit in Atlanta, Georgia, in June 2013.
Source:
Articles in this issue
almost 13 years ago
New Dynamics in Drug Pricing and Prescribingalmost 13 years ago
Climate Change Drives New Opportunities in Outsourcingalmost 13 years ago
Jimmy Carter and Pfizer Mark 15-Year Effort To Help End Blinding Trachomaalmost 13 years ago
Pall Corporation to Acquire ATMI's LifeSciences Business for $185 millionalmost 13 years ago
Cambrex Completes FDA Inspectionalmost 13 years ago
Metrics Appoints New Vice-Presidentalmost 13 years ago
Bridgepoint Development Capital Acquires Quotient Clinicalalmost 13 years ago
GDUFA Off to Good Start, But Storm Clouds on the HorizonAdvertisement
Related to this article

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.

Xiaoling Li, University of the Pacific, discusses how 3D-printed tablets combine multiple APIs and release profiles, scale out instead of up, and use layer-by-layer scanning.

In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.

Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.

Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.

The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.

Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
4
Who Answers for Your Data? Building a Life Sciences Data Mesh
5

